Unknown

Dataset Information

0

Computing membrane-AQP5-phosphatidylserine binding affinities with hybrid steered molecular dynamics approach.


ABSTRACT: In order to elucidate how phosphatidylserine (PS6) interacts with AQP5 in a cell membrane, we developed a hybrid steered molecular dynamics (hSMD) method that involved: (1) Simultaneously steering two centers of mass of two selected segments of the ligand, and (2) equilibrating the ligand-protein complex with and without biasing the system. Validating hSMD, we first studied vascular endothelial growth factor receptor 1 (VEGFR1) in complex with N-(4-Chlorophenyl)-2-((pyridin-4-ylmethyl)amino)benzamide (8ST), for which the binding energy is known from in vitro experiments. In this study, our computed binding energy well agreed with the experimental value. Knowing the accuracy of this hSMD method, we applied it to the AQP5-lipid-bilayer system to answer an outstanding question relevant to AQP5's physiological function: Will the PS6, a lipid having a single long hydrocarbon tail that was found in the central pore of the AQP5 tetramer crystal, actually bind to and inhibit AQP5's central pore under near-physiological conditions, namely, when AQP5 tetramer is embedded in a lipid bilayer? We found, in silico, using the CHARMM 36 force field, that binding PS6 to AQP5 was a factor of 3 million weaker than "binding" it in the lipid bilayer. This suggests that AQP5's central pore will not be inhibited by PS6 or a similar lipid in a physiological environment.

SUBMITTER: Chen LY 

PROVIDER: S-EPMC4523441 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature

altmetric image

Publications

Computing membrane-AQP5-phosphatidylserine binding affinities with hybrid steered molecular dynamics approach.

Chen Liao Y LY  

Molecular membrane biology 20150508 1


In order to elucidate how phosphatidylserine (PS6) interacts with AQP5 in a cell membrane, we developed a hybrid steered molecular dynamics (hSMD) method that involved: (1) Simultaneously steering two centers of mass of two selected segments of the ligand, and (2) equilibrating the ligand-protein complex with and without biasing the system. Validating hSMD, we first studied vascular endothelial growth factor receptor 1 (VEGFR1) in complex with N-(4-Chlorophenyl)-2-((pyridin-4-ylmethyl)amino)benz  ...[more]

Similar Datasets

| S-EPMC4565455 | biostudies-literature
| S-EPMC5666385 | biostudies-literature
| S-EPMC5493307 | biostudies-literature
| S-EPMC1302942 | biostudies-literature
| S-EPMC9333244 | biostudies-literature
| S-EPMC3380839 | biostudies-literature